Related Experiment Video
Updated: Feb 28, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.2K
Are cannabinoids effective for Parkinsons disease?
Gonzalo A Bravo-Soto1, Carlos Juri2
1Centro evidencia UC, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile. Email: cajuri@gmail.com. Address: Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 63, Santiago Centro, Chile.
Medwave
|June 17, 2017
Summary
Cannabinoids likely do not improve Parkinson's disease symptoms or dyskinesia. This review found probable frequent adverse effects in patients using cannabinoids for Parkinson's disease management.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cannabinoids are explored for potential benefits in Parkinson's disease.
- Clinical effectiveness remains under discussion and requires robust evidence.
Purpose of the Study:
- To systematically evaluate the clinical effectiveness of cannabinoids in managing Parkinson's disease.
- To assess the impact of cannabinoids on Parkinson's symptoms and dyskinesia.
Main Methods:
- Searched Epistemonikos database for systematic reviews on cannabinoids for Parkinson's disease.
- Included six systematic reviews comprising eight studies, focusing on four randomized trials.
- Performed meta-analysis and applied the GRADE approach for summarizing findings.
Main Results:
- Cannabinoids likely do not significantly decrease Parkinson's disease symptoms.
- No probable reduction in dyskinesia was observed with cannabinoid use.
- Frequent adverse effects were probably associated with cannabinoid use in Parkinson's patients.
Conclusions:
- Current evidence suggests cannabinoids are unlikely to be beneficial for symptom management in Parkinson's disease.
- The association with adverse effects warrants caution when considering cannabinoids for Parkinson's disease treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
864
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
864
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.0K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.0K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:22Dose-Response Relationship: Potency and Efficacy
6.9K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.9K